UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Amikacin liposome inhalation suspension for chronic Pseudomonas aeruginosa infection in cystic fibrosis

Journal of cystic fibrosis, 2020-03, Vol.19 (2), p.284-291

2020

Volltextzugriff (PDF)

P231 Discontinuation of Pancreatic Enzyme Replacement Therapy (PERT) in children on ivacaftor

Journal of cystic fibrosis, 2020-06, Vol.19, p.S122-S122

2020

Volltextzugriff (PDF)

Chronic rhinosinusitis in the era of CFTR modulator therapy

Journal of cystic fibrosis, 2024-03, Vol.23 (2), p.208-213

2024

Volltextzugriff (PDF)

283 Expectations and experiences of adolescents with cystic fibrosis: Influence of elexacaftor/tezacaftor/ivacaftor on treatment adherence and identity

Journal of cystic fibrosis, 2022-10, Vol.21, p.S168-S169

2022

Volltextzugriff (PDF)

P363 The Modified Shuttle Walk Test in clinically stable children with cystic fibrosis: a 10-year review

Journal of cystic fibrosis, 2019-06, Vol.18, p.S160-S160

2019

Volltextzugriff (PDF)

P091 Development and validation of revised treatment adherence and adherence barrier questionnaires for children with cystic fibrosis aged 6 through 11

Journal of cystic fibrosis, 2023-06, Vol.22, p.S91-S92

2023

Volltextzugriff (PDF)

WS11.04 Measuring barriers to adherence among people with cystic fibrosis starting treatment with elexacaftor/tezacaftor/ivacaftor: results from the RECOVER study

Journal of cystic fibrosis, 2023-06, Vol.22, p.S23-S23

2023

Volltextzugriff (PDF)

P170 Trikafta® modulates release of extracellular vesicles in cystic fibrosis

Journal of cystic fibrosis, 2023-06, Vol.22, p.S116-S117

2023

Volltextzugriff (PDF)

EPS7.04 Sinus MRI demonstrates sustained treatment response in children after elexacaftor/tezacaftor/ivacaftor (E/T/I) therapy of a similar magnitude to oxygen-enhanced (OE-) lung MRI

Journal of cystic fibrosis, 2024-06, Vol.23, p.S54-S54

2024

Volltextzugriff (PDF)

P160 Study to Evaluate the Additional Gains of Upper and Lower Lobe Sampling in children with Cystic Fibrosis (SEAGULLS): safety and microbiological yield

Journal of cystic fibrosis, 2020-06, Vol.19, p.S101-S101

2020

Volltextzugriff (PDF)

Investigating serum extracellular vesicles in Cystic Fibrosis

Journal of cystic fibrosis, 2023-07, Vol.22 (4), p.674-679

2023

Volltextzugriff (PDF)

524 Striking a BAL-NS: Combining metagenomics with culture methods shows nasal swabs to be a good proxy for bronchoalveolar lavage in microbial and pathogen surveillance

Journal of cystic fibrosis, 2022-10, Vol.21, p.S293-S293

2022

Volltextzugriff (PDF)

141 Factors associated with significantly corrected sweat chloride in people with cystic fibrosis taking elexacaftor-tezacaftor-ivacaftor—results from the PROMISE and RECOVER studies

Journal of cystic fibrosis, 2023-10, Vol.22, p.S74-S75

2023

Volltextzugriff (PDF)

WS19.02 Impact of corrected Multiple Breath nitrogenWashout (MBW) software on assessment of under/unventilated lung units (UVLU) with the MBWShX

Journal of cystic fibrosis, 2022-06, Vol.21, p.S37

2022

Volltextzugriff (PDF)

EPS6.07 Longitudinal impact of elexacaftor/tezacaftor/ivacaftor on abdominal symptoms assessed with the CFAbd-Score and on intestinal inflammation in people with cystic fibrosis aged ≥ 12 years – The RECOVER study

Journal of cystic fibrosis, 2023-06, Vol.22, p.S54-S54

2023

Volltextzugriff (PDF)

WS06.05 The volume of trapped air (VTA) from multiple breath washout (MBW) substantially underestimates the extent of trapped air (TA) demonstrated with spirometry-controlled computed tomography

Journal of cystic fibrosis, 2023-06, Vol.22, p.S13-S13

2023

Volltextzugriff (PDF)

P127 Twenty years and counting: longitudinal trends in real-world primary outcomes for people with cystic fibrosis in Ireland and the evolution of a registry

Journal of cystic fibrosis, 2023-06, Vol.22, p.S103-S103

2023

Volltextzugriff (PDF)

P038 Direct measurement of short-term adherence to elexacaftor/tezacaftor/ivacaftor and changes in sweat chloride levels – results from the RECOVER Study

Journal of cystic fibrosis, 2023-06, Vol.22, p.S75-S75

2023

Volltextzugriff (PDF)

148 Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in children aged 6 and older with cystic fibrosis and at least one F508del allele: final results from a 192-week extension study

Journal of cystic fibrosis, 2024-09, Vol.23, p.S82-S83

2024

Volltextzugriff (PDF)

126 Adherence to elexacaftor/tezacaftor/ivacaftor and clinical outcomes in people with cystic fibrosis—the RECOVER study

Journal of cystic fibrosis, 2024-09, Vol.23, p.S69-S69

2024

Volltextzugriff (PDF)

125 Improvement in abdominal symptoms (CFAbd-Score) and gut inflammation over 12 months of treatment with elexacaftor/tezacaftor/ivacaftor in children with CF aged 6 to 11—results from the RECOVER study

Journal of cystic fibrosis, 2024-09, Vol.23, p.S68-S68

2024

Volltextzugriff (PDF)

142 Clinical outcomes after 2 years of treatment with elexacaftor/tezacaftor/ivacaftor in children aged 6 to −11 with cystic fibrosis—The RECOVER Study

Journal of cystic fibrosis, 2024-09, Vol.23, p.S78-S79

2024

Volltextzugriff (PDF)

146 Liver disease outcomes in people with cystic fibrosis after 2 years of elexacaftor/tezacaftor/ivacaftor—results from the RECOVER trial

Journal of cystic fibrosis, 2024-09, Vol.23, p.S81-S82

2024

Volltextzugriff (PDF)

569: Agreement of spirometry-controlled computed tomography scans with multiple breath washout with short extension

Journal of cystic fibrosis, 2021-11, Vol.20, p.S269-S270

2021

Volltextzugriff (PDF)

1 – 25 von 76

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieJournal Of Cystic Fibrosis

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(76)
Mit Volltextzugriff
(76)

Publikationsform

Artikel
(76)

Sprache

Englisch
(76)

Erscheinungsjahr

n.n

Kollektion

EZB Free E-Journals
(76)
Ingenta
(76)
Elsevier ScienceDirect Journals Complete
(76)
MEDLINE
(6)

Neu hinzugefügt

... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

The natural history of cystic fibrosis liver disease a prospective cohort study

Amikacin liposome inhalation suspension for chronic Pseudomonas aeruginosa infection in cystic fibrosis

P231 Discontinuation of Pancreatic Enzyme Replacement Therapy (PERT) in children on ivacaftor

Chronic rhinosinusitis in the era of CFTR modulator therapy

283 Expectations and experiences of adolescents with cystic fibrosis: Influence of elexacaftor/tezacaftor/ivacaftor on treatment adherence and identity

P363 The Modified Shuttle Walk Test in clinically stable children with cystic fibrosis: a 10-year review

P091 Development and validation of revised treatment adherence and adherence barrier questionnaires for children with cystic fibrosis aged 6 through 11

WS11.04 Measuring barriers to adherence among people with cystic fibrosis starting treatment with elexacaftor/tezacaftor/ivacaftor: results from the RECOVER study

P170 Trikafta® modulates release of extracellular vesicles in cystic fibrosis

EPS7.04 Sinus MRI demonstrates sustained treatment response in children after elexacaftor/tezacaftor/ivacaftor (E/T/I) therapy of a similar magnitude to oxygen-enhanced (OE-) lung MRI

P160 Study to Evaluate the Additional Gains of Upper and Lower Lobe Sampling in children with Cystic Fibrosis (SEAGULLS): safety and microbiological yield

Investigating serum extracellular vesicles in Cystic Fibrosis

524 Striking a BAL-NS: Combining metagenomics with culture methods shows nasal swabs to be a good proxy for bronchoalveolar lavage in microbial and pathogen surveillance

141 Factors associated with significantly corrected sweat chloride in people with cystic fibrosis taking elexacaftor-tezacaftor-ivacaftor—results from the PROMISE and RECOVER studies

WS19.02 Impact of corrected Multiple Breath nitrogenWashout (MBW) software on assessment of under/unventilated lung units (UVLU) with the MBWShX

EPS6.07 Longitudinal impact of elexacaftor/tezacaftor/ivacaftor on abdominal symptoms assessed with the CFAbd-Score and on intestinal inflammation in people with cystic fibrosis aged ≥ 12 years – The RECOVER study

WS06.05 The volume of trapped air (VTA) from multiple breath washout (MBW) substantially underestimates the extent of trapped air (TA) demonstrated with spirometry-controlled computed tomography

P127 Twenty years and counting: longitudinal trends in real-world primary outcomes for people with cystic fibrosis in Ireland and the evolution of a registry

P038 Direct measurement of short-term adherence to elexacaftor/tezacaftor/ivacaftor and changes in sweat chloride levels – results from the RECOVER Study

148 Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in children aged 6 and older with cystic fibrosis and at least one F508del allele: final results from a 192-week extension study

126 Adherence to elexacaftor/tezacaftor/ivacaftor and clinical outcomes in people with cystic fibrosis—the RECOVER study

125 Improvement in abdominal symptoms (CFAbd-Score) and gut inflammation over 12 months of treatment with elexacaftor/tezacaftor/ivacaftor in children with CF aged 6 to 11—results from the RECOVER study

142 Clinical outcomes after 2 years of treatment with elexacaftor/tezacaftor/ivacaftor in children aged 6 to −11 with cystic fibrosis—The RECOVER Study

146 Liver disease outcomes in people with cystic fibrosis after 2 years of elexacaftor/tezacaftor/ivacaftor—results from the RECOVER trial

569: Agreement of spirometry-controlled computed tomography scans with multiple breath washout with short extension

Aktive Filter

Suchergebnisse filtern